Boehncke, 2015
64
|
Psoriasis |
363 |
Langley, 2014
65
|
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials |
208 |
Hawkes, 2017
66
|
Psoriasis pathogenesis and the development of novel targeted immune therapies |
194 |
Rendon, 2019
67
|
Psoriasis Pathogenesis and Treatment |
146 |
Lowes, 2013
68
|
The IL‐23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses |
129 |
Lande, 2014
69
|
The antimicrobial peptide LL37 is a T‐cell autoantigen in psoriasis |
127 |
Martin, 2013
70
|
The emerging role of IL‐17 in the pathogenesis of psoriasis: Preclinical and clinical findings |
126 |
Harden, 2015
71
|
The immunogenetics of Psoriasis: A comprehensive review |
125 |
Armstrong, 2020
72
|
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis |
107 |
Takeshita, 2017
73
|
Psoriasis and comorbid diseases: Epidemiology |
105 |